Joanna Kufel-Grabowska

Dr. Joanna Kufel-Grabowska

Clinic of Oncology and Radiotherapy, Gdańsk Medical University, Gdańsk, Pomorskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
GDGrzegorz Dworacki
Grzegorz Dworacki
JKJoanna Kufel-Grabowska
Joanna Kufel-Grabowska
CWCezary Watala
Cezary Watala
WKWojciech Kozubski
Wojciech Kozubski
MLMaria Lukasik
Maria Lukasik
The white blood cell count and mean platelet volume determined shortly after the symptom onset are known as independent predictors for clinical outcome after stroke. In the present study we sought to evaluate the prognostic value of platelet-derived inflammatory biomarkers measured prospectively after an ischaemic event. Using five-colour flow cytometry, the platelet surface expression of CD40L, CD62P and subpopulations of leukocyte-platelet aggregates were assessed in 93 stroke patients on the first (V0), 10th (V1) and 90th (V2) day after stroke, and once in 65 disease controls. The clinical outcome was evaluated using the Scandinavian Stroke Scale (SSS) and modified Rankin Scale (mRS) at the same time points as blood sampling and 24 months after the event. Patients with either CD40L surface expression or the percentage of monocyte-platelet aggregates (M-plt) in the third tertile (T3) at V0 had a significantly lower score on the SSS at V1. Patients with the percentage M-plt at V0 higher than the median value of M-plt in controls were at increased risk of SSS < 40 at V1 (odds ratio: 2.6; 95% confidence interval [CI]: 1.4 – 8.7; p=0.006). Patients with the percentage of M-plt in T3 at V0 showed progressive decline in survival (hazard ratio [HR]: 1.6; 95% CI: 1.1–1.9; p=0.02) and a significantly higher number of recurrent vascular events (HR: 2.64; 95% CI: 1.3–3.2; p=0.02) when compared to the first tertile. In conclusion, increased levels of M-plt could be a predictive marker for both early outcome and long-term prognosis while increased CD40L was correlated with worse clinical outcome. The preliminary results of this study were presented in part during a poster session at the 62nd Annual Meeting of the American Academy of Neurology in Toronto, 7–17 April 2010.

Agnieszka Beata Dawczak-DębickaAgnieszka Beata Dawczak-Dębicka
Agnieszka Beata Dawczak-Dębicka
JKJoanna Kufel-Grabowska
Joanna Kufel-Grabowska
MBMikołaj Bartoszkiewicz
Mikołaj Bartoszkiewicz
APAdrian Perdyan
Adrian Perdyan
JJJacek Jassem
Jacek Jassem
Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Increasing patients’ awareness and providing easier access to public information result in greater interest in alternative anticancer or unproven supportive therapies. Fear of cancer and limited trust in the treating physician are also important reasons leading patients to seek these methods. Trust and good communication are essential to achieving truthful collaboration between physicians and patients. Given the popularity of CAM, better knowledge about these alternative practices may help oncologists discuss this issue with their patients. This article objectively reviews the most common unconventional therapies used by cancer patients.

1 November 2011 in Thrombosis Research
Verified
Journal Article
Closed access
MLMaria Lukasik
Maria Lukasik
GDGrzegorz Dworacki
Grzegorz Dworacki
SMSlawomir Michalak
Slawomir Michalak
JKJoanna Kufel-Grabowska
Joanna Kufel-Grabowska
JGJacek Golanski
Jacek Golanski
WKWojciech Kozubski
Wojciech Kozubski

19 July 2011 in Platelets
Verified
Journal Article
Closed access
PDF file
MLMaria Lukasik
Maria Lukasik
GDGrzegorz Dworacki
Grzegorz Dworacki
SMSlawomir Michalak
Slawomir Michalak
JKJoanna Kufel-Grabowska
Joanna Kufel-Grabowska
CWCezary Watala
Cezary Watala
WKWojciech Kozubski
Wojciech Kozubski
Although the platelet activation profile after stroke is a well-known issue, the platelet reactivity assessed prospectively after ischaemic stroke still remains equivocal. The aim of this study was to evaluate the reactivity of platelets in response to stimulation with thrombin receptor-activating peptide (TRAP) at 1, 10 and 90 days after ischaemic stroke and to compare it with results obtained in control groups. We determined the increment in surface expression of CD62P, CD40L and monocyte- and granulocyte-platelet aggregate formation using five-colour flow cytometry in 86 subjects after an ischaemic event, in 62 disease controls, and in 38 healthy volunteers. We assessed the plasma levels of CD62P and CD40L soluble forms. In patients after stroke a significantly lower increment in CD62P surface expression (p < 0.01) and higher increments in both CD40L platelet surface expression (p < 0.01) and monocyte-platelet aggregate percentage (p < 0.01) were found at every studied time point, as compared with the control groups. Plasma levels of soluble CD62P (sCD62P) and soluble CD40L (sCD40L) were increased in stroke subjects in both the acute and the subacute phase of the stroke and they dropped to levels observed in controls at day 90 after the ischaemic incident. In all studied groups a positive correlation was noted between plasma levels of sCD62P and sCD40L. In conclusion, while at 3-month follow-up the levels of soluble forms normalize in stroke patients, the profile of platelet reactivity in response to activation with TRAP differs from that observed in the controls despite the secondary stroke prevention.

20 July 2021 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
JKJoanna Kufel-Grabowska
Joanna Kufel-Grabowska
MBMikołaj Bartoszkiewicz
Mikołaj Bartoszkiewicz
RRRodryg Ramlau
Rodryg Ramlau
MLMaria Litwiniuk
Maria Litwiniuk
Background. The initial approval of the Pfizer/BioNTech and Moderna vaccines by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) marked a milestone in the fight against the COVID-19 pandemic. The increased public debate about the vaccine development process and vaccine side effects has activated the anti-vaccine community, which has begun to spread conspiracy theories about vaccine safety. Objectives. Our study is the first to investigate the awareness of Polish patients suffering from various chronic diseases, mainly cancer, about vaccination against SARS-CoV-2. Materials and methods. An anonymous survey was made available from November 2020 to February 2021 to representatives of patient organizations through social media (Facebook) and to patients in the Chemotherapy Department of the Clinical Hospital in Poznan. The survey was completed by 836 patients. The majority of the survey respondents had cancer (77%, n = 644), and almost 1/5 of the respondents indicated hypertension (15.7%, n = 131) as well as depression and/or anxiety disorders (11.1%, n = 93). Results. Less than half of the respondents (43.5%, n = 364) believed that SARS-CoV-2 vaccines were safe (40.4%, n = 260, among cancer patients; 53.9%, n = 104, among patients with other medical conditions). More than half of the respondents (60.5%, n = 506) intended to be vaccinated against SARS-CoV-2 (58.8%, n = 378, among cancer patients; 66.3%, n = 128, among patients with other medical conditions). Fear of vaccine complications and lack of belief in vaccine effectiveness were prevalent among both cancer patients and patients with other medical conditions. Conclusions. The vast majority of cancer and medical patients wanted to be vaccinated against COVID-19. More than half of the respondents did not believe that the COVID-19 vaccine would be safe for them. Education of cancer and medical patients on the safety and effectiveness of the vaccine, as well as the use of additional protective measures against infection, is an extremely important element of prevention during the COVID-19 pandemic.

19 October 2016 in Breast Care
Verified
Journal Article
Closed access
MWMateusz Wichtowski
Mateusz Wichtowski
PPPaweł Michał Potocki
Paweł Michał Potocki
JKJoanna Kufel-Grabowska
Joanna Kufel-Grabowska
JSJoanna Streb
Joanna Streb
DMDawid Murawa
Dawid Murawa
Background: Chest wall recurrence (CWR) from breast cancer after mastectomy is a difficult to treat disease. Electrochemotherapy (ECT) provides a safe, efficient, and non-invasive locoregional treatment approach in this setting. Case Report: A 61-year-old woman presented with unresectable breast cancer recurrence to the skin and subcutaneous tissue for which numerous lines of treatment were unsuccessful. Between February 2015 and May 2015, the patient underwent 3 courses of ECT after which a spectacular regression of the cutaneous metastatic foci was observed. After an overall observation period of 12 weeks, complete clinical remission was achieved. Conclusion: ECT can be proposed as an effective and safe locoregional therapy for breast cancer CWR and provides an alternative treatment modality to conventional therapies, especially in the case of multiple cutaneous and subcutaneous lesions.